Try our beta test site
3 studies found for:    Lymphoma OR CLL | CUDC-907
Show Display Options
Rank Status Study
1 Recruiting Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma
Conditions: Multiple Myeloma;   Lymphoma
Intervention: Drug: CUDC-907
2 Recruiting Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Conditions: Lymphoma;   Neuroblastoma;   Brain Tumor;   Solid Tumor
Intervention: Drug: CUDC-907
3 Recruiting Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With RR DLBCL, Including Patients With MYC Alterations
Condition: Relapsed and/or Refractory Diffuse Large B-cell Lymphoma
Interventions: Drug: CUDC-907;   Drug: Rituximab

Study has passed its completion date and status has not been verified in more than two years.